Patients' prognoses are excellent with a 95% five-year survival rate when treated. However, the risk of nodal metastases is 1% to 3% in mucosal lesions and up to 20% in submucosal lesions.
Sin embargo, el riesgo de existencia de metástasis ganglionares es del 1 al 3% en lesiones mucosas y hasta del 20% para las submucosas.